Each year, more than 2.3 million women worldwide are diagnosed with breast cancer, including over 370,000 in the United States alone. Despite decades of progress, far too many women are still diagnosed after the disease has already taken hold, including many with no family history or known risk factors. A revolutionary new platform is poised to change that. The FDA has granted De Novo authorization to Clairity Breast, the first-ever
AI-powered platform that predicts a woman’s risk of developing breast cancer over the next five years using only a standard mammogram. With support from the Breast Cancer Research Foundation (BCRF), Clairity, Inc. is poised to launch the first predictive imaging model in breast cancer. This historic milestone is a major advance in prevention, equity, and personalized care.
The Breast Cancer Research Foundation is dedicated to ending breast cancer by advancing the world’s most promising research. This year, BCRF is the largest private funder of breast cancer research—and metastatic breast cancer research—worldwide and is the highest-rated breast cancer research organization in the country.